| Not Yet Recruiting | A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, NCT07515469 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Not Yet Recruiting | A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence NCT07475026 | Tianjin Medical University Cancer Institute and Hospital | Phase 3 |
| Not Yet Recruiting | A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepa NCT07535840 | Tongji Hospital | N/A |
| Not Yet Recruiting | Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin NCT07518706 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Recruiting | A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Comb NCT07521852 | TaiRx, Inc. | Phase 2 |
| Not Yet Recruiting | Intelligence System for Predicting Atezolizumab-Bevacizumab Response and Clinical Outcomes in Unresectable Hep NCT07495735 | First Affiliated Hospital of Wenzhou Medical University | — |
| Not Yet Recruiting | Lenvatinib and Pembrolizumab With or Without BCAA in Unresectable HCC NCT07412054 | Fudan University | Phase 2 |
| Not Yet Recruiting | Surgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular Carcinoma (SWITCH) NCT07410715 | West China Hospital | — |
| Recruiting | A Multicenter Prospective Study on the Performance of Spectral CT for Evaluating Treatment Response After TACE NCT07351669 | Zhongda Hospital | — |
| Not Yet Recruiting | Efficacy and Safety of Radiotherapy Combined With Tislelizumab and Anlotinib in the Treatment of Hepatocellula NCT07363512 | Henan Cancer Hospital | Phase 2 |
| Recruiting | Phase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma NCT07310173 | Zhejiang Hisun Pharmaceutical Co. Ltd. | Phase 2 |
| Not Yet Recruiting | The Efficacy of Preoperative Oral Administration of Lactobacillus Reuteri Combined With Preoperative Neoadjuva NCT07306481 | Fujian Cancer Hospital | N/A |
| Recruiting | The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With NCT07285850 | Eastern Hepatobiliary Surgery Hospital | Phase 2 / Phase 3 |
| Not Yet Recruiting | EDN Combined With TACE/HAIC and Second-Line Immune-Targeted Treatment Versus TACE/HAIC Alone in Locally Advanc NCT07187284 | Zhongda Hospital | Phase 1 / Phase 2 |
| Recruiting | [68Ga]Ga-PSMA PET/CT in Hepatocellular Carcinoma: Impact of Multiparametric Dynamic Whole-body Imaging and Kin NCT06999837 | Nantes University Hospital | N/A |
| Recruiting | A Study of GV20-0251 in Advanced or Refractory Solid Tumors NCT07106827 | West China Hospital | Phase 1 |
| Not Yet Recruiting | A Prospective Observational Cohort Study on Dynamic CD8+ T-cell Profiling and Multi-omics Biomarkers for Predi NCT07117279 | Tongji Hospital | — |
| Not Yet Recruiting | Clinical Trials of the Hepatitis B Sandwich Combination Therapy for Treating Patients Infected With Hepatitis NCT07088133 | Shanghai Zhongshan Hospital | N/A |
| Not Yet Recruiting | Development and Prospective Validation of a Heterogeneous Treatment Effect-Based Decision Model for Transarter NCT07109336 | Zhongda Hospital | N/A |
| Not Yet Recruiting | Predictors of HCC in Post-HCV Cirrhotic Patients After SVR NCT07097870 | Sohag University | — |
| Recruiting | Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA) NCT05690048 | Michael Dill | Phase 2 |
| Not Yet Recruiting | Downstaging Prediction Model for HCC NCT07058649 | Beijing Tsinghua Chang Gung Hospital | — |
| Recruiting | Study of GV20-0251 in Participants With Solid Tumor Malignancies NCT07070518 | GV20 Therapeutics | Phase 1 / Phase 2 |
| Recruiting | A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Me NCT07376707 | Hefei TG ImmunoPharma Co., Ltd. | Phase 1 |
| Enrolling By Invitation | Evaluation of Efficacy and Safety of Immune Check Point Inhibitors in Hepatocellular Carcinoma Patients in Ain NCT07088081 | Ain Shams University | — |
| Recruiting | Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC NCT06999707 | Chang Gung Memorial Hospital | Phase 2 |
| Recruiting | Proton Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC NCT06999694 | Chang Gung Memorial Hospital | Phase 2 |
| Not Yet Recruiting | Iparomlimab and Tuvonralimab Injection (QL1706) Combined With Bevacizumab for Postoperative Adjuvant Therapy i NCT06958484 | The Affiliated Hospital of Xuzhou Medical University | Phase 2 |
| Recruiting | FGF19 Overexpression Combination Unified Study in HCC-19 NCT06978933 | RenJi Hospital | Phase 2 |
| Recruiting | Impact of Radiotherapy on ctDNA in Patients With Hepatocellular Carcinoma NCT06885879 | Chinese University of Hong Kong | — |
| Not Yet Recruiting | An Exploratory Clinical Study on Neoadjuvant Treatment of Hepatocellular Carcinoma with QL1706 Combined with L NCT06884982 | Northern Jiangsu People's Hospital | Phase 2 |
| Recruiting | ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC NCT07157969 | Peking Union Medical College Hospital | Phase 2 |
| Not Yet Recruiting | QL1706 As Second-line Treatment in Patients with Advanced Hepatocellular Carcinoma NCT06822985 | Wan-Guang Zhang | Phase 1 |
| Recruiting | ctDNA Monitoring in Patients With HCC and mCRC NCT07001085 | Medical University of Warsaw | N/A |
| Not Yet Recruiting | Part of the Modern Art Study NCT06768242 | Erasmus Medical Center | N/A |
| Recruiting | The Impact of Emotional Stress on Immunotherapy Outcomes in Liver Cancer Patients: A Multi-Cohort Study NCT07141056 | Guilin Medical University, China | — |
| Recruiting | A Phase I Study of LXP1788 Injection with Advanced Solid Tumors. NCT06883539 | LaunXP Biomedical Co., Ltd. | Phase 1 |
| Recruiting | Mts105 for Advanced Hepatocellular Carcinoma NCT06689540 | Shen Lin | Phase 1 |
| Recruiting | Non-invasive Assessment for Outcome Prediction in Patients With Hepatocellular Carcinoma NCT07036874 | Chinese University of Hong Kong | — |
| Recruiting | Needle-based Percutaneous Ablation of Liver Tumors. NCT06689670 | inTumo Therapeutics, Inc. | N/A |
| Recruiting | Universal CAR-T Cells (REVO-UWD-03) for Advanced Hepatocellular Carcinoma and Lung Cancer NCT06653023 | Wondercel Biotech (ShenZhen) | EARLY_Phase 1 |
| Not Yet Recruiting | Measuring the Density of Iodine in Lipiodol Depositions: Detecting an Invisible Residual Tumor After Conventio NCT06602986 | Pak Emirates Military Hospital | N/A |
| Active Not Recruiting | Sequential TACE-SBRT Combined With Targeted Immunotherapy for Patients With Intermediate to Advanced Liver Can NCT07230080 | Nanfang Hospital, Southern Medical University | — |
| Not Yet Recruiting | Prediction and Prognostic Analysis of Liver Abscess Formation After Transcatheter Arterial Chemoembolization f NCT06483594 | Shengjing Hospital | — |
| Not Yet Recruiting | HAIC Combined With PD-L1 Plus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma After Immunoth NCT06375317 | Yehua Shen | Phase 2 |
| Recruiting | Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by by Percutaneous Ab NCT06045975 | Assistance Publique - Hôpitaux de Paris | Phase 2 |
| Completed | Microvascular Invasion Artificial Intelligence Prediction Via Contrast-enhanced Ultrasound With Explainability NCT06760494 | Chinese PLA General Hospital | — |
| Recruiting | Efficacy & Safety of Anticoagulants in Cirrhosis ± HCC NCT07132515 | Mansoura University | Phase 4 |
| Completed | Real-world Study of Lenalidomide After First-line Treatment Lenvatinib With PD-1 in Advanced HCC NCT07184424 | Beijing Tsinghua Chang Gung Hospital | N/A |
| Completed | Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patien NCT05665348 | Federation Francophone de Cancerologie Digestive | Phase 2 / Phase 3 |
| Active Not Recruiting | Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors NCT05651022 | Indaptus Therapeutics, Inc | Phase 1 / Phase 2 |
| Recruiting | Sarcopenia and Systemic Therapy in HCC NCT06805552 | IRCCS Azienda Ospedaliero-Universitaria di Bologna | — |
| Recruiting | Efficacy and Safety of Radiotherapy in Oligoprogressive HCC Following First-line PD-1 Therapy NCT06870942 | Shanghai Zhongshan Hospital | Phase 2 |
| Recruiting | Can Hepatic-splenic Elastography Predict the Risk of Hepatocellular Recurrence After Radiofrequency Ablation? NCT06777017 | IRCCS Azienda Ospedaliero-Universitaria di Bologna | — |
| Active Not Recruiting | Prospective Evaluation of a Locked Risk-Stratified Surveillance Strategy for Extrahepatic Metastasis in Hepato NCT07444905 | Tongji Hospital | — |
| Completed | Recurrence Patterns and Cost-Effectiveness of Surgical Approaches in Early-Stage Hepatocellular Carcinoma NCT06776185 | Chen Xiaoping | — |
| Recruiting | Intra Artherial Therapies in Treatment of Primary Liver Diseases: an Observational Study NCT06774690 | IRCCS Azienda Ospedaliero-Universitaria di Bologna | — |
| Completed | HAIC in Combination With PD-1 Inhibitors and Lenvatinib for High Tumor Burden Advanced HCC (CHANCE2416) NCT06631326 | First Hospital of China Medical University | — |
| Completed | PD-1 Inhibitor Combined With 125I Seed Implantation for Hepatocellular Carcinoma's Extrahepatic Metastasis: Ef NCT06991907 | Jiangxi Provincial Cancer Hospital | N/A |
| Recruiting | PROtocol of Metabolic and Cryptogenic livEr Disease regisTry for intEgration of Omic Studies NCT04371042 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Recruiting | Downstaging Unresectable Hepatocellular Carcinoma to Resectable Disease With Combined Immunotherapy and Stereo NCT07305428 | The University of Hong Kong | N/A |
| Completed | Comparison of Gd-EOB-DTPA-enhanced MRI and Contrast-enhanced Ultrasound for Measuring Tumor Size of Solitary H NCT06437457 | Anhui Medical University | — |